
NBIX Valuation
Neurocrine Biosciences Inc
- Overview
- Forecast
- Valuation
- Earnings
NBIX Relative Valuation
NBIX's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, NBIX is overvalued; if below, it's undervalued.
Historical Valuation
Neurocrine Biosciences Inc (NBIX) is now in the Undervalued zone, suggesting that its current forward PE ratio of 18.34 is considered Undervalued compared with the five-year average of 22.58. The fair price of Neurocrine Biosciences Inc (NBIX) is between 134.49 to 196.61 according to relative valuation methord. Compared to the current price of 134.19 USD , Neurocrine Biosciences Inc is Undervalued By 0.22%.
Relative Value
Fair Zone
134.49-196.61
Current Price:134.19
0.22%
Undervalued
18.34
PE
1Y
3Y
5Y
Trailing
Forward
22.61
EV/EBITDA
Neurocrine Biosciences Inc. (NBIX) has a current EV/EBITDA of 22.61. The 5-year average EV/EBITDA is 23.33. The thresholds are as follows: Strongly Undervalued below 7.77, Undervalued between 7.77 and 15.55, Fairly Valued between 31.11 and 15.55, Overvalued between 31.11 and 38.89, and Strongly Overvalued above 38.89. The current Forward EV/EBITDA of 22.61 falls within the Historic Trend Line -Fairly Valued range.
20.19
EV/EBIT
Neurocrine Biosciences Inc. (NBIX) has a current EV/EBIT of 20.19. The 5-year average EV/EBIT is 24.58. The thresholds are as follows: Strongly Undervalued below 10.43, Undervalued between 10.43 and 17.50, Fairly Valued between 31.65 and 17.50, Overvalued between 31.65 and 38.73, and Strongly Overvalued above 38.73. The current Forward EV/EBIT of 20.19 falls within the Historic Trend Line -Fairly Valued range.
4.67
PS
Neurocrine Biosciences Inc. (NBIX) has a current PS of 4.67. The 5-year average PS is 6.05. The thresholds are as follows: Strongly Undervalued below 3.56, Undervalued between 3.56 and 4.81, Fairly Valued between 7.30 and 4.81, Overvalued between 7.30 and 8.54, and Strongly Overvalued above 8.54. The current Forward PS of 4.67 falls within the Undervalued range.
18.74
P/OCF
Neurocrine Biosciences Inc. (NBIX) has a current P/OCF of 18.74. The 5-year average P/OCF is 22.20. The thresholds are as follows: Strongly Undervalued below 14.83, Undervalued between 14.83 and 18.52, Fairly Valued between 25.89 and 18.52, Overvalued between 25.89 and 29.57, and Strongly Overvalued above 29.57. The current Forward P/OCF of 18.74 falls within the Historic Trend Line -Fairly Valued range.
21.76
P/FCF
Neurocrine Biosciences Inc. (NBIX) has a current P/FCF of 21.76. The 5-year average P/FCF is 24.50. The thresholds are as follows: Strongly Undervalued below 16.89, Undervalued between 16.89 and 20.69, Fairly Valued between 28.31 and 20.69, Overvalued between 28.31 and 32.11, and Strongly Overvalued above 32.11. The current Forward P/FCF of 21.76 falls within the Historic Trend Line -Fairly Valued range.
Neurocrine Biosciences Inc (NBIX) has a current Price-to-Book (P/B) ratio of 5.22. Compared to its 3-year average P/B ratio of 5.65 , the current P/B ratio is approximately -7.68% higher. Relative to its 5-year average P/B ratio of 6.59, the current P/B ratio is about -20.76% higher. Neurocrine Biosciences Inc (NBIX) has a Forward Free Cash Flow (FCF) yield of approximately 3.72%. Compared to its 3-year average FCF yield of 3.21%, the current FCF yield is approximately 16.03% lower. Relative to its 5-year average FCF yield of 2.97% , the current FCF yield is about 25.06% lower.
5.22
P/B
Median3y
5.65
Median5y
6.59
3.72
FCF Yield
Median3y
3.21
Median5y
2.97
Competitors Valuation Multiple
The average P/S ratio for NBIX's competitors is 7.24, providing a benchmark for relative valuation. Neurocrine Biosciences Inc Corp (NBIX) exhibits a P/S ratio of 4.67, which is -35.46% above the industry average. Given its robust revenue growth of 11.12%, this premium appears unsustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
Revenue Growth
Market Cap
Performance Decomposition
1Y
3Y
5Y
Market capitalization of NBIX decreased by 5.21% over the past 1 year. The primary factor behind the change was an increase in P/E Change from 27.03 to 45.21.
The secondary factor is the Revenue Growth, contributed 11.12%to the performance.
Overall, the performance of NBIX in the past 1 year is driven by P/E Change. Which is more unsustainable.
People Also Watch

MORN
Morningstar Inc
286.810
USD
+1.50%

PAA
Plains All American Pipeline LP
18.730
USD
+1.46%

BAP
Credicorp Ltd
238.000
USD
+1.28%

ACM
AECOM
113.000
USD
-0.74%

GGG
Graco Inc
84.570
USD
+0.11%

EWBC
East West Bancorp Inc
103.240
USD
-0.61%

APTV
Aptiv PLC
68.240
USD
-2.33%

BIP
Brookfield Infrastructure Partners LP
31.420
USD
-0.57%

RVTY
Revvity Inc
94.470
USD
-0.60%

SMMT
Summit Therapeutics Inc
26.740
USD
-2.59%
FAQ

Is Neurocrine Biosciences Inc (NBIX) currently overvalued or undervalued?
Neurocrine Biosciences Inc (NBIX) is now in the Undervalued zone, suggesting that its current forward PE ratio of 18.34 is considered Undervalued compared with the five-year average of 22.58. The fair price of Neurocrine Biosciences Inc (NBIX) is between 134.49 to 196.61 according to relative valuation methord. Compared to the current price of 134.19 USD , Neurocrine Biosciences Inc is Undervalued By 0.22% .

What is Neurocrine Biosciences Inc (NBIX) fair value?

How does NBIX's valuation metrics compare to the industry average?

What is the current P/B ratio for Neurocrine Biosciences Inc (NBIX) as of Jul 30 2025?

What is the current FCF Yield for Neurocrine Biosciences Inc (NBIX) as of Jul 30 2025?

What is the current Forward P/E ratio for Neurocrine Biosciences Inc (NBIX) as of Jul 30 2025?
